Dr. Yael Mossé receives recognition for project dedicated to researching and potentially developing new therapies for undruggable solid tumorsPHILADELPHIA, March 6, 2024 /PRNewswire/ -- An interdisciplinary, global team of scientists led by Yael Mossé, MD, Professor of Pediatrics in the Cancer Center at Children's Hospital of Philadelphia (CHOP), has been selected as one of five research teams from all over the world to receive funds from Cancer Grand Challenges, a funding initiative co-founded by the National Cancer Institute and Cancer Research UK.

2024年3月6日，Yael Mossé博士因致力于研究和潜在开发不可治疗实体瘤新疗法的项目而获得认可费城，这是一个由费城儿童医院（CHOP）癌症中心儿科教授Yael Mossé博士领导的跨学科全球科学家团队，已被选为来自世界各地的五个研究团队之一，接受癌症大挑战基金的资助，该基金由英国国家癌症研究所和英国癌症研究所共同创立。

Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer..

莫斯的国际团队将获得高达2500万美元的资金，用于为以前无法治愈的儿童癌症开发具有变革性的新疗法。。

Continue Reading

继续阅读

International team led by Dr. Yael Mossé, Professor of Pediatrics in the Cancer Center at Children's Hospital of Philadelphia, will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.

由费城儿童医院癌症中心儿科教授Yael Mossé博士领导的国际团队将获得高达2500万美元的资金，用于开发针对以前无法治疗的儿童癌症的变革性新疗法。

Last year, 176 global teams submitted bold ideas for tackling some of the most pressing challenges in cancer research and care. Twelve teams were shortlisted, and the project 'Developing a suite of oncoprotein degraders for childhood solid cancers,' nicknamed Team KOODAC3, emerged as one of five teams to receive funding after a year-long rigorous selection process.

去年，176个全球团队提交了大胆的想法，以应对癌症研究和护理中一些最紧迫的挑战。12个团队入围，绰号为KOODAC3团队的“开发一套用于儿童实体癌的癌蛋白降解剂”项目是经过一年严格筛选过程后获得资金的五个团队之一。

The team unites the expertise of researchers from the United States, Austria, France, Germany and the United Kingdom to tackle the challenge of oncogene-addicted solid tumors in children..

该团队汇集了来自美国、奥地利、法国、德国和英国的研究人员的专业知识，以应对儿童致癌基因成瘾性实体瘤的挑战。。

While survival rates for many childhood cancers have improved dramatically through the combination of standard chemotherapy and radiation therapy, survivors are often burdened with life threatening toxicities related to those therapies. Genetic discoveries related to cancer have transformed how many types of tumors are treated.

虽然通过标准化疗和放射治疗的结合，许多儿童癌症的生存率得到了显着提高，但幸存者往往承受着与这些治疗相关的危及生命的毒性。与癌症相关的基因发现改变了治疗的肿瘤类型。

Cancer is caused by genetic mutations that transform normal genes into oncogenes. These oncogenes are then translated into proteins that are not typically found in the cell, known as oncoproteins..

癌症是由将正常基因转化为癌基因的基因突变引起的。然后，这些癌基因被翻译成通常在细胞中找不到的蛋白质，称为癌蛋白。。

Several drugs have been developed to treat different tumors by targeting oncogenes and their associated oncoproteins. Despite advances in this field, a critical challenge has been the difficulty of targeting proteins responsible for causing solid tumors related to childhood cancers. As a result, cure rates for most solid tumors have not improved at the rate of other types of cancer.KOODAC3 aims to develop drugs that break down or 'degrade' five of the most significant oncoproteins in children with high-risk oncogene-driven cancers, including neuroblastoma, medulloblastoma, Ewing sarcoma, fibrolamellar hepatocellular carcinoma, rhabdomyosarcoma and other cancers that deregulate these essential oncoproteins.

已经开发了几种通过靶向癌基因及其相关癌蛋白来治疗不同肿瘤的药物。尽管在这一领域取得了进展，但一个关键的挑战是难以靶向导致与儿童癌症相关的实体瘤的蛋白质。因此，大多数实体瘤的治愈率并没有提高到其他类型癌症的治愈率。KOODAC3旨在开发药物，分解或“降解”患有高风险癌基因驱动癌症的儿童中最重要的五种癌蛋白，包括神经母细胞瘤，髓母细胞瘤，尤因肉瘤，纤维板层肝细胞癌，横纹肌肉瘤和其他使这些必需癌蛋白失调的癌症。

The team is addressing this challenge by extending an ongoing collaboration with Nurix Therapeutics, a leading biopharmaceutical company focused on degrader drugs, providing a streamlined route for clinical translation of discoveries made by Team KOODAC3. Collectively, this consortium has the ambitious goal of developing oral drugs that will be deployed world-wide in partnership with a robust international patient advocacy committee that will inform outreach to childhood cancer communities globally.'Our team is deeply honored to have been selected as one of the five to receive funding from the Cancer Grand Challenges initiative,' said Mossé.

该团队正在通过扩展与Nurix Therapeutics的持续合作来应对这一挑战，Nurix Therapeutics是一家专注于降解药物的领先生物制药公司，为KOODAC3团队的发现提供了简化的临床翻译途径。总的来说，这个财团有一个雄心勃勃的目标，即开发口服药物，该药物将与一个强大的国际患者倡导委员会合作，在全球范围内部署，该委员会将为全球儿童癌症社区的推广提供信息。”莫斯说，我们的团队非常荣幸被选为五个接受癌症大挑战计划资助的团队之一。

'Team KOODAC3 was brought together with the goal of identifying new strategies for treating high-risk pediatric cancers with a high unmet need. Each of the projects that applied for this funding were worthy, so we do not take this award lightly and we are committed to bringing our expertise together with the goal of developing paradigm-altering safe and effective new therapies for currently lethal childhood solid cancers.'Addition.

“KOODAC3团队的目标是确定治疗高风险儿科癌症的新策略，这些癌症的需求尚未得到满足。申请这笔资金的每个项目都是值得的，因此我们不会轻视这个奖项，我们致力于将我们的专业知识结合起来，以开发改变范式的安全有效的新疗法，治疗目前致命的儿童实体癌。”添加。